aplastic anemia | Page 2 | Aplastic Anemia & MDS International Foundation Return to top.

aplastic anemia

Maximilian Stahl, MD

Stahl, Maximilian
Hematologist/Oncologist
Dana-Farber Cancer Institute

Dr. Stahl graduated from Hannover Medical School in Hannover, Germany. He received his internal medicine residency training at the Yale School of Medicine where he also served as a chief medical resident. He then completed his Hematology and Oncology fellowship training at the Memorial Sloan Kettering Cancer Center in New York City. He is currently a member of the Adult Leukemia Group at Dana-Farber Cancer Institute and also a member of the faculty at Harvard Medical School. 

Long-term efficacy and safety of romiplostim in refractory aplastic anemia: follow-up of a phase 2/3 study

Author(s): 
Mitani K, Lee JW, Jang JH, Tomiyama Y, Miyazaki K, Nagafuji K, Usuki K, Uoshima N, Fujisaki T, Kosugi H, Matsumura I, Sasaki K, Kizaki M, Sawa M, Hidaka M, Kobayashi N, Ichikawa S, Yonemura Y, Murotani K, Shimizu M, Matsuda A, Ozawa K, Nakao S
Primary Author: 
Mitani K
Journal Title: 
Blood Advances
Original Publication Date: 
Dec 2023
Bone Marrow Disease(s): 

Plain language summary of RACE study results: addition of eltrombopag to standard treatment of severe aplastic anemia

Author(s): 
de Latour RP, Kulasekararaj A, Iacobelli S, Griffin M, Halkes CJ, Dufour C, Risitano AM
Primary Author: 
de Latour RP
Journal Title: 
Immunotherapy
Original Publication Date: 
Dec 2023

What is this summary about?: Severe

Bone Marrow Disease(s): 

Conditional survival and standardized mortality ratios of patients with severe aplastic anemia surviving at least one year after hematopoietic cell transplantation or immunosuppressive therapy

Author(s): 
Nakamura R, Patel BA, Kim S, Wong FL, Armenian SH, Groarke EM, Keesler DA, Hebert KM, Heim M, Eapen M, Young NS
Primary Author: 
Nakamura R
Journal Title: 
Haematologica
Original Publication Date: 
Dec 2023

Immunosuppressive treatment (IST) and hematopoietic cell transplant (HCT) are standard therapies for severe

Bone Marrow Disease(s): 

Deciphering treatment patterns in non-severe/moderate aplastic anemia: an international observational study

Author(s): 
Fattizzo B, Gurnari C, Cassanello G, Bortolotti M, Awada H, Giammarco S, Consonni D, Sica S, Gandhi S, Trikha R, Large J, Salter S, Maciejewski JP, Barcellini W, Kulasekararaj AG
Primary Author: 
Fattizzo B
Journal Title: 
Leukemia
Original Publication Date: 
Dec 2023

Non-severe

Bone Marrow Disease(s): 
Share with addtoany.com.